Stability Testing for Drug Product Hantaan and Puumala DNA Plasmids in support of USAMRIID

The U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a Firm Fixed Price, sole source Contract on behalf of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to Ajinomoto Althea, Inc. located in San Diego, CA, under the authority as prescribed in FAR 13.106-1(b) (1), only one source reasonably available that will satisfy agency requirements. This requirement is for the continuation of stability testing for drug product Hantaan and Puumala DNA plasmids, in support of USAMRIID, currently being provided by Ajinomoto Althea, Inc.

USAMRIID conducts research using DNA plasmids manufactured by and under current stability testing with Ajinomoto Althea, Inc. Additionally, USAMRIID is currently in the middle of an on-going clinical trial utilizing Hantaan and Puumala DNA plasmids currently under stability testing with Ajinomoto Althea, Inc. under W81XWH18C0040. Due to the continued research and on-going clinical trial, the continued use of the same vendor currently providing the stability testing is required.

This notice of intent is NOT a request for quotations (RFQ) and no solicitation document exists for the requirement; however, if a vendor challenges the basis for this requirement, please submit a capability statement that includes sufficient detail and with convincing evidence that clearly demonstrates the capability to provide these services.  A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response.  A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government.  Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source procurement.

Capability statements are due no later than 1300 Eastern Time, 14 July 2023. Capability statements shall be submitted via email ONLY as a Microsoft Word or Adobe PDF attachment to the following email addresses christina.m.lewis14.civ@health.mil and jayme.l.fletcher2.civ@health.mil. No phone calls will be accepted.